The grant is allocated across a global group of research institutions and partners, with AdaptVac coordinating the effort and contributing its proprietary Virus-like Particle (VLP) platform to the vaccine development. Over five years, the project will advance a vaccine candidate through preclinical studies and into planned Phase I/II clinical trials in Gabon and the Netherlands.

Filoviruses cause frequent, unpredictable outbreaks with fatality rates of up to 90%, primarily affecting populations in Central and East Africa. A broadly protective, “all-in-one” vaccine could be transformative in protecting high-risk groups, including healthcare workers.

If the project is successful and the vaccine candidate progresses to outlicensing for further development, ExpreS2ion may benefit financially through its ownership stake in AdaptVac. Outlicensing agreements typically include milestone payments and royalties, which could provide future revenue streams for ExpreS2ion and its shareholders. Importantly, this type of non-dilutive public funding supports the de-risking of early-stage vaccine candidates—moving them from a low probability of approval to a more validated, investable stage where success rates increase materially. This progression significantly enhances the asset’s potential value in future partnerships or licensing deals.

ExpreS2ion CEO Bent Frandsen comments:
“This consortium grant underscores AdaptVac’s leadership and the potential of its VLP technology. It also reinforces the value of our partnership and investment in AdaptVac. Should this candidate succeed, it could help address one of the world’s most serious epidemic threats—and potentially create long-term value for our shareholders.”

For more information, see: https://cepi.net/pioneering-research-develop-all-one-vaccine-against-some-worlds-most-deadly-diseases

About AdaptVac
AdaptVac ApS was founded in 2017 and today owned by ExpreS2ion Biotechnologies (34%) and NextGen Vaccines (66%), the latter owned by the inventors of the proprietary and clinical Phase III-validated viral capsid Virus-like virus particle (cVLP) platform technology spun out from the University of Copenhagen. The Company aims to accelerate the development of highly efficient therapeutic and prophylactic vaccines within high value segments of oncology, infectious diseases, and immunological disorders. Please visit: www.AdaptVac.com

Certified Adviser
Svensk Kapitalmarknadsgranskning AB